The Claim
Among individuals living with HIV who initiate statin therapy, those with a pre-statin low-density lipoprotein cholesterol (LDL-C) level of ≥190 mg/dL are more likely to achieve a ≥30% reduction in LDL-C (59.1%) compared to those with unknown statin indications (34.6%), indicating that baseline LDL-C level is a strong predictor of statin response in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you have HIV and your 'bad' cholesterol is already really high (190 or more), you're much more likely to see a big drop in it after starting a statin pill than someone whose reason for taking statins isn't clear — so your starting cholesterol level might tell doctors how well the medicine will work for you.
See the scientific wording
Among persons living with HIV initiating statin therapy, those with pre-statin low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are more likely to achieve a ≥30% reduction in LDL-C (59.1%) compared to those with unknown statin indications (34.6%), suggesting baseline LDL-C level is a strong predictor of statin response in this population.
What the research says
1 studyThe study found that HIV patients with very high cholesterol before starting statins were more likely to get a big drop in cholesterol after taking the medicine, which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.